High-dose chemotherapy + stem cells for multiple myeloma

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1387, 2003-01, pp. : 13-13

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

High-dose tamoxifen is not a feasible option in patients with relapsed or refractory multiple myeloma

By  

Inpharma, Vol. 1, Iss. 1439, 2004-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

End of the road for high-dose chemotherapy plus stem cell rescue

By  

Inpharma, Vol. 1, Iss. 1230, 2000-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Pharmacodynamics of High-Dose Chemotherapy

By  

Current Drug Metabolism, Vol. 2, Iss. 1, 2001-03 ,pp. : 53-66

Bentham Science Publishers

Access to resources Recommend Favorite

Prevention of Emesis from Multiple-Day and High-Dose Chemotherapy Regimens

By Navari Rudolph M.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 5, Iss. 1, 2007-01 ,pp. : 51-59

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

High-dose chemotherapy: no survival benefit

By  

Inpharma, Vol. 1, Iss. 1229, 2000-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite